tiprankstipranks
Trending News
More News >
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
US Market
Advertisement

Arcutis Biotherapeutics (ARQT) AI Stock Analysis

Compare
876 Followers

Top Page

ARQT

Arcutis Biotherapeutics

(NASDAQ:ARQT)

Rating:58Neutral
Price Target:
$17.50
▲(12.76% Upside)
Arcutis Biotherapeutics' strong revenue growth and positive earnings call sentiment are significant strengths, contributing to a promising outlook. However, profitability challenges and valuation concerns moderate the overall score. Technical indicators support a bullish trend, but caution is advised due to approaching overbought conditions.
Positive Factors
Insurance Coverage
The entire Zoryve portfolio is covered by the three national PBMs, and management reported that over 80% of prescriptions are covered by insurance.
M&A Potential
The success of the Zoryve commercialization and label expansion opportunities represent an increasingly attractive M&A target for larger derm players.
Sales Performance
Total product sales beat consensus, with management reporting 19% prescription growth, and GTN remains stable in the 50% range.
Negative Factors
Medicare Reimbursement
Medicare reimbursement has stalled due to IRA-related changes, though Medicare accounts for less than 25% of the company’s TAM.
Product Development
The company disclosed that it is discontinuing development of ARQ-255 following Phase 1b results in alopecia areata did not meet the company's threshold for advancing development.

Arcutis Biotherapeutics (ARQT) vs. SPDR S&P 500 ETF (SPY)

Arcutis Biotherapeutics Business Overview & Revenue Model

Company DescriptionArcutis Biotherapeutics, Inc. (ARQT) is a biopharmaceutical company dedicated to developing and commercializing innovative dermatological therapies. The company focuses on creating treatments for immune-mediated dermatological diseases and conditions. Arcutis's core products include topical creams and ointments designed to address conditions such as psoriasis and eczema, aiming to improve patient outcomes through advanced drug formulations.
How the Company Makes MoneyArcutis Biotherapeutics generates revenue primarily through the sale of its dermatological products. The company's revenue model is centered around the commercialization of its proprietary topical treatments. Key revenue streams include sales from both prescription products and potential collaborations with other pharmaceutical companies. Significant factors contributing to its earnings are the successful development and market penetration of its products, ongoing clinical trials that expand its product line, and strategic partnerships that enhance distribution and market reach.

Arcutis Biotherapeutics Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call for Arcutis Biotherapeutics highlighted strong revenue and prescription growth driven by the ZORYVE franchise and recent FDA approval. Despite seasonal factors expected to moderate growth and challenges in Medicare Part D coverage, the positive cash flow and strategic plans suggest a promising outlook.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Arcutis reported net product revenues of $81.5 million in Q2 2025, representing a 28% quarter-on-quarter growth and a 164% increase compared to the same quarter in 2024.
FDA Approval for ZORYVE Foam
Received FDA approval for ZORYVE foam 0.3% for the treatment of plaque psoriasis of the scalp and body, marking the fifth FDA approval for ZORYVE in the last 3 years.
Increased Prescription Volume
ZORYVE prescription volume reached a record high with nearly 200,000 total prescriptions in the quarter, reflecting a year-over-year volume increase of 117% and a quarter-over-quarter increase of 13%.
Positive Cash Flow from Operations
The company reported a positive net cash flow from operating activities of $325,000 in Q2 2025.
Negative Updates
Seasonality Impact on Growth
Anticipated moderation in sequential growth rate in Q3 2025 due to seasonality factors such as summer vacations and reduced flaring of inflammatory skin conditions.
Medicare Part D Coverage Challenges
Progress with Medicare Part D plans is slow due to financial disruptions from the Inflation Reduction Act, leading to a more protracted process for coverage decisions.
Halted Development of ARQ-255
The company decided to halt further development of ARQ-255 following disappointing results from the Phase Ib trial.
Company Guidance
In the Arcutis Biotherapeutics 2025 Second Quarter Financial Results Conference Call, the company reported strong financial performance and strategic progress. Net product revenues reached $81.5 million, marking a 28% increase from the previous quarter and a 164% growth compared to the second quarter of 2024. This growth was driven by increased demand for ZORYVE, with prescriptions reaching 16,000 weekly scripts and a total of nearly 200,000 prescriptions in the quarter, reflecting a 13% quarter-over-quarter increase and a 117% year-over-year increase. The company's gross-to-net rates remained stable, supported by strong insurance coverage. Arcutis also highlighted its strategic focus on expanding ZORYVE's indications, with a fifth FDA approval for ZORYVE foam 0.3% for plaque psoriasis of the scalp and body in May. The company is pursuing further label expansions, particularly in pediatric atopic dermatitis, with an upcoming PDUFA date in October for ZORYVE cream 0.05% for children aged 2 to 5. Arcutis is on track for cash flow breakeven in 2026, supported by disciplined capital allocation and a strategic focus on leveraging its development and commercialization capabilities.

Arcutis Biotherapeutics Financial Statement Overview

Summary
Arcutis Biotherapeutics shows strong revenue growth, but persistent net losses and negative cash flows highlight ongoing operational challenges. The balance sheet shows reasonable leverage, but declining equity indicates potential financial stress if profitability does not improve.
Income Statement
35
Negative
Arcutis Biotherapeutics shows a significant improvement in total revenue, growing from $3.7 million in 2022 to $212.8 million in TTM 2025. However, the company remains unprofitable with a net loss of $129.7 million in TTM 2025, resulting in negative net profit margins. The gross profit margin is strong at 88.4% for TTM 2025, indicating efficient cost management, but operating losses continue to weigh heavily on the overall financial health.
Balance Sheet
45
Neutral
The company has a moderate debt-to-equity ratio of 0.78 in TTM 2025, showing a balanced approach to leveraging its equity. However, stockholders' equity has decreased over the years, reflecting ongoing net losses. The equity ratio stands at 41.5%, suggesting a reasonable proportion of equity in the asset base, but the declining trend in equity is a concern.
Cash Flow
30
Negative
Arcutis Biotherapeutics exhibits negative operating cash flow of $110.9 million in TTM 2025, which remains a challenge alongside a negative free cash flow of $116.7 million. The cash flow to net income ratios indicate that cash flow generation is not yet aligned with net income improvements, posing liquidity risks if trends persist.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue263.46M196.54M59.61M3.69M0.000.00
Gross Profit234.74M177.41M54.62M2.93M-763.00K-455.00K
EBITDA-68.53M-109.63M-227.43M-294.55M-205.59M-135.22M
Net Income-93.27M-140.04M-262.14M-311.46M-206.36M-135.68M
Balance Sheet
Total Assets352.43M348.89M341.37M449.27M408.15M298.27M
Cash, Cash Equivalents and Short-Term Investments191.13M227.96M271.86M409.59M387.06M284.44M
Total Debt110.16M110.58M205.92M202.54M77.56M4.96M
Total Liabilities213.46M191.35M252.70M239.69M110.47M27.65M
Stockholders Equity138.97M157.54M88.67M209.58M297.68M270.62M
Cash Flow
Free Cash Flow-71.32M-112.30M-247.49M-281.00M-175.62M-113.35M
Operating Cash Flow-65.49M-112.16M-247.06M-257.71M-174.63M-113.03M
Investing Cash Flow148.83M28.82M180.23M-87.20M-75.95M-181.82M
Financing Cash Flow-95.24M66.20M101.32M301.80M281.95M298.14M

Arcutis Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price15.52
Price Trends
50DMA
14.92
Positive
100DMA
14.39
Positive
200DMA
13.96
Positive
Market Momentum
MACD
0.25
Positive
RSI
51.69
Neutral
STOCH
18.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARQT, the sentiment is Positive. The current price of 15.52 is above the 20-day moving average (MA) of 15.49, above the 50-day MA of 14.92, and above the 200-day MA of 13.96, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 51.69 is Neutral, neither overbought nor oversold. The STOCH value of 18.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARQT.

Arcutis Biotherapeutics Risk Analysis

Arcutis Biotherapeutics disclosed 73 risk factors in its most recent earnings report. Arcutis Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Arcutis Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
$2.12B11.8927.58%17.74%59.96%
65
Neutral
$2.70B-28.43%
62
Neutral
$1.62B-5.38%26.90%62.72%
58
Neutral
$1.90B-57.33%99.50%65.91%
51
Neutral
$7.85B-0.18-40.01%2.28%22.97%-2.05%
50
Neutral
$2.11B-86.34%30.14%-10.08%
45
Neutral
$2.29B-39.69%-100.00%1.62%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ARQT
Arcutis Biotherapeutics
15.52
5.02
47.81%
DNLI
Denali Therapeutics
15.27
-9.85
-39.21%
HRMY
Harmony Biosciences Holdings
36.89
0.54
1.49%
IMCR
Immunocore Holdings
32.22
-3.86
-10.70%
NAMS
NewAmsterdam Pharma Company
24.05
8.14
51.16%
RXRX
Recursion Pharmaceuticals
4.70
-1.37
-22.57%

Arcutis Biotherapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting
Neutral
Jun 17, 2025

On June 12, 2025, Arcutis Biotherapeutics held its 2025 Annual Meeting of Stockholders, where all proposed matters were approved by the shareholders. The meeting included the election of three Class II directors, ratification of Ernst & Young LLP as the independent auditor, and approval of executive compensation. Additionally, the company revised its Non-Employee Director Compensation Plan to enhance its corporate governance practices and attract qualified board members.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025